This segment focuses on the research, development, and commercialization of neuromodulators, primarily DaxibotulinumtoxinA (DAXXIFY), for aesthetic applications. Research and development activities include clinical trials for treating glabellar lines, forehead lines, and lateral canthal lines. The technology utilizes botulinum toxin type A to temporarily reduce the appearance of wrinkles. This segment addresses the growing demand for non-invasive cosmetic procedures, offering patients a long-lasting alternative to existing treatments. Market positioning is strong due to DAXXIFY's extended duration of effect compared to competitors. Future opportunities include expanding the product portfolio and geographic reach. Regulatory aspects involve FDA approval and ongoing post-market surveillance. Partnerships with aesthetic practices and clinics are crucial for distribution and patient access.

This segment concentrates on the development and commercialization of DaxibotulinumtoxinA for therapeutic indications. Research and development efforts are focused on clinical trials for conditions such as cervical dystonia, upper limb spasticity, and plantar fasciitis. The technology leverages the properties of botulinum toxin to alleviate muscle spasms and pain. This segment aims to improve the quality of life for patients suffering from debilitating neurological and musculoskeletal disorders. Market positioning is based on providing effective and potentially longer-lasting treatment options. Future opportunities include expanding into new therapeutic areas like migraine and exploring combination therapies. Regulatory aspects involve obtaining approvals from regulatory bodies like the FDA. Collaborations with neurologists, pain specialists, and rehabilitation centers are essential for patient access and treatment.